Skip to main content

Table 3 Baseline LRT pathogens: ASPECT-NP participants who were failing prior antibacterial therapy

From: Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

ITT population (primary efficacy population)a

LRT pathogen, n (%)b

C/T (N = 53)

MEM (N = 40)

Total (N = 93)

Any LRT pathogen

49 (92.5)

32 (80.0)

81 (87.1)

Gram-negative

49 (92.5)

31 (77.5)

80 (86.0)

 Pseudomonas aeruginosa

13 (24.5)

5 (12.5)

18 (19.4)

 Enterobacterales

37 (69.8)

21 (52.5)

58 (62.4)

  ESBL + Enterobacterales

16 (30.2)

8 (20.0)

24 (25.8)

  Klebsiella pneumoniae

19 (35.8)

14 (35.0)

33 (35.5)

  ESBL + Klebsiella pneumoniae

14 (26.4)

8 (20.0)

22 (23.7)

  Escherichia coli

11 (20.8)

3 (7.5)

14 (15.1)

  ESBL + Escherichia coli

3 (5.7)

0

3 (3.2)

  Proteus mirabilis

5 (9.4)

1 (2.5)

6 (6.5)

  ESBL + Proteus mirabilis

3 (5.7)

1 (2.5)

4 (4.3)

  Serratia marcescens

3 (5.7)

2 (5.0)

5 (5.4)

  Klebsiella aerogenes

3 (5.7)

1 (2.5)

4 (4.3)

  Acinetobacter baumannii

11 (20.8)

10 (25.0)

21 (22.6)

  Stenotrophomonas maltophilia

0

2 (5.0)

2 (2.2)

No LRT pathogen identified

4 (7.5)

8 (20.0)

12 (12.9)

mITT population (secondary efficacy population)c

LRT pathogen, n (%)b

C/T (N = 39)

MEM (N = 24)

Total (N = 63)

Any LRT pathogen

39 (100)

24 (100)

63 (100)

Gram-negative

39 (100)

24 (100)

63 (100)

 Pseudomonas aeruginosa

11 (28.2)

4 (16.7)

15 (23.8)

 Enterobacterales

30 (76.9)

17 (70.8)

47 (74.6)

  ESBL + Enterobacterales

10 (25.6)

6 (25.0)

16 (25.4)

  Enterobacter cloacae

2 (5.1)

2 (8.3)

4 (6.3)

  Escherichia coli

10 (25.6)

2 (8.3)

12 (19.0)

  ESBL + Escherichia coli

2 (5.1)

0

2 (3.2)

  Klebsiella (Enterobacter) aerogenes

2 (5.1)

1 (4.2)

3 (4.8)

  Klebsiella pneumoniae

12 (30.8)

11 (45.8)

23 (36.5)

  ESBL + Klebsiella pneumoniae

7 (17.9)

6 (25.0)

13 (20.6)

  Proteus mirabilis

5 (12.8)

1 (4.2)

6 (9.5)

  ESBL + Proteus mirabilis

3 (7.7)

1 (4.2)

4 (6.3)

  Serratia marcescens

3 (7.7)

2 (8.3)

5 (7.9)

  Acinetobacter baumannii

4 (10.3)

3 (12.5)

7 (11.1)

  Stenotrophomonas maltophilia

0

2 (8.3)

2 (3.2)

No LRT pathogen identified

0

0

0

  1. C/T Ceftolozane/tazobactam, ESBL Extended-spectrum β-lactamase, ITT Intention-to-treat, LRT Lower respiratory tract, MEM Meropenem, mITT Microbiologic intention-to-treat, n Number of study participants with the specific pathogen, N Number of study participants in the specific treatment arm and analysis population with ≥ 1 baseline LRT
  2. aStudy participants were eligible for inclusion into the ITT population regardless of whether they had a baseline pathogen, the type of pathogen, and pathogen susceptibility
  3. bIncidence ≥ 5%
  4. cStudy participants were eligible for inclusion into the mITT population only if baseline LRT cultures yielded ≥ 1 gram-negative or streptococcal respiratory pathogen that was susceptible to ≥ 1 study drug
Back to article page

Critical Care

ISSN: 1364-8535